-
公开(公告)号：US09408905B2
公开(公告)日：2016-08-09
申请号：US14320923
申请日：2014-07-01
发明人： Feng Yao
IPC分类号： A61K39/245 , A61K39/12 , C12N7/00 , A61K39/00 , A61K35/76 , A61K35/763 , G01N33/569 , C12N15/869
CPC分类号： A61K39/245 , A61K35/763 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/545 , A61K2039/57 , C12N7/00 , C12N15/869 , C12N15/8695 , C12N2710/16011 , C12N2710/16021 , C12N2710/16034 , C12N2710/16062 , C12N2710/16071 , C12N2710/16611 , C12N2710/16621 , C12N2710/16622 , C12N2710/16634 , C12N2710/16661 , C12N2710/16662 , C12N2830/003 , C12N2830/006 , G01N33/56994
摘要： The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.
摘要翻译： 本发明涉及可用于免疫患者的生殖器疱疹疫苗的单纯疱疹病毒2型病毒。
-
2.发明申请公开(公告)号：US20150290165A1
公开(公告)日：2015-10-15
申请号：US14748608
申请日：2015-06-24
发明人： Craig J. EAGLE , H. Craig DEES , Eric A. WACHTER , Jamie SINGER
IPC分类号： A61K31/352 , A61K47/02 , A61K38/20 , C12N7/00 , A61K38/19 , A61K39/00 , A61K39/245 , A61K39/395 , A61K38/21
CPC分类号： A61K39/3955 , A61K31/352 , A61K31/365 , A61K38/193 , A61K38/20 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/21 , A61K38/212 , A61K38/217 , A61K39/0005 , A61K39/0011 , A61K39/245 , A61K39/39558 , A61K45/06 , A61K47/02 , A61K47/60 , A61K2039/505 , C07K16/30 , C12N7/00 , C12N2710/16021 , C12N2710/16034
摘要： A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
-
3.发明申请RECOMBINANT EQUINE HERPESVIRUS-1 VACCINE CONTAINING MUTATED GLYCOPROTEIN C AND USES THEREOF 有权含有突变型糖蛋白C的重组方案HERPESVIRUS-1疫苗及其用途公开(公告)号：US20150190502A1
公开(公告)日：2015-07-09
申请号：US14543300
申请日：2014-11-17
申请人： MERIAL LIMITED
IPC分类号： A61K39/245 , C12N7/00
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/5254 , A61K2039/552 , C07K14/005 , C12N7/00 , C12N2710/16021 , C12N2710/16034 , C12N2710/16722 , C12N2710/16734 , C12N2710/16762
摘要： The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.
摘要翻译： 本发明提供含有重组EHV-1的组合物或疫苗，其在动物中引发针对马疱疹病毒的免疫应答，包括包含所述重组EHV-1的组合物，针对马疱疹病毒的疫苗接种方法，以及用于此类方法和组合物的试剂盒 。
-
公开(公告)号：US20140154215A1
公开(公告)日：2014-06-05
申请号：US14174521
申请日：2014-02-06
申请人： Amgen Inc.
发明人： Robert S. COFFIN
IPC分类号： C12N15/86
CPC分类号： C12N7/00 , A61K35/763 , A61K48/00 , A61K2039/55516 , A61K2039/55522 , C12N15/86 , C12N2710/16021 , C12N2710/16033 , C12N2710/16632 , C12N2710/16643
摘要： The present invention provides a herpes virus with improved oncolytic properties which comprises a gene encoding an immunomodulatory cytokine and which lacks a functional ICP34.5 gene and a functional ICP47 encoding gene.
摘要翻译： 本发明提供具有改进的溶瘤性质的疱疹病毒，其包含编码免疫调节细胞因子的基因，并且缺少功能性ICP34.5基因和功能性ICP47编码基因。
-
公开(公告)号：US6149918A
公开(公告)日：2000-11-21
申请号：US529881
申请日：1995-09-18
IPC分类号： A61K39/245 , C07K16/08 , C12N7/00 , A61K39/12
CPC分类号： C12N7/00 , A61K39/12 , A61K39/245 , C07K16/085 , A61K2039/545 , A61K2039/55555 , A61K2039/55566 , C12N2710/16021 , C12N2710/16034 , C12N2710/16434
摘要： A human lymphoma cell line containing a human herpesvirus type 8 (HHV-8) capable of in vitro growth and which produces HHV-8 virus particles upon induction of lytic viral growth is provided. Virus produced by the cell line of the invention is useful for the production of antibodies to an HHV-8 virus particle, viral protein, or viral peptide. Methods of screening a biological sample for the presence of HHV-8 virus particles, viral protein, or viral peptide from a human suspected of being infected with HHV-8 are provided as are methods of screening a biological sample of the human for antibodies to HHV-8.
摘要翻译： 提供了含有能够体外生长并在诱导溶解病毒生长时产生HHV-8病毒颗粒的人疱疹病毒8型（HHV-8）的人类淋巴瘤细胞系。 由本发明的细胞系产生的病毒可用于产生针对HHV-8病毒颗粒，病毒蛋白或病毒肽的抗体。 提供了从怀疑被HHV-8感染的人中筛选生物样品中存在HHV-8病毒颗粒，病毒蛋白或病毒肽的方法，例如筛选人的生物学样品用于HHV抗体的方法 -8。
-
公开(公告)号：US5756281A
公开(公告)日：1998-05-26
申请号：US157811
申请日：1993-11-23
申请人： William John Martin
发明人： William John Martin
IPC分类号： A61K39/00 , C07K14/03 , C07K14/15 , C12N5/08 , C12N7/00 , C12Q1/70 , G01N33/569 , C12N5/06 , C12N7/02 , G01N33/48
CPC分类号： G01N33/56983 , C07K14/005 , C12N7/00 , C12Q1/701 , C12Q1/702 , C12Q1/705 , A61K39/00 , C12N2710/16021 , C12N2710/16022 , C12N2710/16622 , C12N2740/10022
摘要： A method of detecting a stealth virus is provided by culturing a sample under conditions in which any stealth virus in the sample is able to induce a cytopathic effect. A method for culturing a virus is also provided by (a) cocentrifuging a sample of the virus with a permissive cell line of indicator cells; (b) inoculating the cell mixture into culture vessels; (c) adding viral enhancing medium to the culture; and (d) detecting in vitro a cytopathic effect in the permissive cell line.
摘要翻译： 通过在样品中任何隐形病毒能够诱导细胞病变效应的条件下培养样品来提供检测隐形病毒的方法。 通过（a）用指示剂细胞的允许细胞系将病毒样品进行离心，还提供培养病毒的方法; （b）将细胞混合物接种到培养容器中; （c）向培养物中加入病毒增强培养基; 和（d）体外检测允许细胞系中的细胞病变效应。
-
公开(公告)号：US20230372474A1
公开(公告)日：2023-11-23
申请号：US18031102
申请日：2021-10-14
申请人： Ceva Sante Animale
发明人： Motoyuki Esaki , Vilmos Palya , Timea Tatar , Zoltan Penzes
IPC分类号： A61K39/245 , C12N7/00 , C12N15/86 , A61P31/22
CPC分类号： A61K39/245 , C12N7/00 , C12N15/86 , A61P31/22 , C12N2710/16034 , C12N2710/16043 , C12N2710/16021 , C12N2760/18122 , C12N2760/16122 , A61K2039/5256
摘要： The present invention relates to recombinant herpes viruses comprising recombinant nucleotide sequences encoding at least two different antigens. The invention is particularly suited for producing vaccines to immunize avian species against avian pathogen(s).
-
公开(公告)号：US09931396B2
公开(公告)日：2018-04-03
申请号：US15164010
申请日：2016-05-25
申请人： GESVAL, S.A.
IPC分类号： A61K39/245 , C12N7/00 , A61K39/12 , A61K39/00
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/552 , C12N7/00 , C12N2710/16021 , C12N2710/16022 , C12N2710/16034 , C12N2710/16043 , C12N2710/16051 , C12N2710/16062 , C12N2800/204
摘要： The present invention relates to a recombinant Koi herpesvirus (KHV), methods for the production of such KHV, cells comprising such KHV and the use of such KHV as vector and in vaccines for the prevention and/or therapeutic treatment of a disease in fish caused by Koi herpesvirus in carp such as Cyprinus carpio carpio or Cyprinus carpio koi.
-
9.发明申请公开(公告)号：US20180055926A1
公开(公告)日：2018-03-01
申请号：US15804357
申请日：2017-11-06
发明人： Craig J. EAGLE , H. Craig DEES , Eric A. WACHTER , Jamie SINGER
IPC分类号： A61K39/395 , A61K39/00 , A61K31/352 , A61K31/365 , C12N7/00 , C07K16/30 , A61K47/02 , A61K45/06 , A61K39/245 , A61K38/21 , A61K38/20 , A61K38/19
CPC分类号： A61K39/3955 , A61K31/352 , A61K31/365 , A61K38/193 , A61K38/20 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/21 , A61K38/212 , A61K38/217 , A61K39/0005 , A61K39/0011 , A61K39/245 , A61K39/39558 , A61K45/06 , A61K47/02 , A61K47/60 , A61K2039/505 , C07K16/30 , C12N7/00 , C12N2710/16021 , C12N2710/16034
摘要： A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
-
10.发明授权公开(公告)号：US09808524B2
公开(公告)日：2017-11-07
申请号：US14748634
申请日：2015-06-24
发明人： Craig J. Eagle , H. Craig Dees , Eric A. Wachter , Jamie Singer
IPC分类号： A61K39/395 , A61K31/352 , A61K38/21 , C07K16/30 , A61K31/365 , A61K38/19 , A61K38/20 , A61K39/00 , A61K39/245 , A61K45/06 , A61K47/02 , A61K47/60 , C12N7/00
CPC分类号： A61K39/3955 , A61K31/352 , A61K31/365 , A61K38/193 , A61K38/20 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/21 , A61K38/212 , A61K38/217 , A61K39/0005 , A61K39/0011 , A61K39/245 , A61K39/39558 , A61K45/06 , A61K47/02 , A61K47/60 , A61K2039/505 , C07K16/30 , C12N7/00 , C12N2710/16021 , C12N2710/16034
摘要： A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.025 秒)
